CSPC Pharma (01093): CSPC Pharma's net loss attributable to shareholders for the year 2025 is 241 million yuan.
Shinepharm Group (01093) announced that its subsidiary Shinepharm Innovations Pharmaceuticals Co., Ltd. (Shinepharm Innovations) achieved a revenue of 2.158 billion yuan for the year ended December 31, 2025, an increase of 8.93% year-on-year. The net loss attributable to the shareholders of the listed company was 241 million yuan, compared to a net profit of 53.726 million yuan in the same period last year, with a basic loss per share of 0.1731 yuan.
CSPC PHARMA (01093) announced that its subsidiary, Shiyao Chuangxin Pharmaceutical Co., Ltd. (Shiyao Chuangxin), achieved revenue of 2.158 billion yuan for the year ended December 31, 2025, representing a year-on-year growth of 8.93%. The net loss attributable to the shareholders of the listed company was 241 million yuan, compared to a net profit of 53.726 million yuan in the same period last year. Basic loss per share was 0.1731 yuan.
Related Articles
US Stock Market Move | Futu Holdings Ltd. Sponsored ADR Class A (FUTU.US) rose more than 7% with a 101.9% year-on-year increase in net profit for 2025.
US Stock Market Move | Semiconductor stocks surged, Intel Corporation (INTC.US) rose more than 4%.
HAITIAN INT'L(01882) releases its 2025 annual performance with a profit attributable to shareholders of 3.301 billion yuan, an increase of 7.2% year-on-year.
US Stock Market Move | Futu Holdings Ltd. Sponsored ADR Class A (FUTU.US) rose more than 7% with a 101.9% year-on-year increase in net profit for 2025.
US Stock Market Move | Semiconductor stocks surged, Intel Corporation (INTC.US) rose more than 4%.
HAITIAN INT'L(01882) releases its 2025 annual performance with a profit attributable to shareholders of 3.301 billion yuan, an increase of 7.2% year-on-year.
